The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI Alliance

Lee, Lisa A.; Franzel, Lauren; Atwell, Jessica E.; Datta, S. Deblina; Friberg, Ingrid K.; Goldie, Sue J.; Reef, Susan E.; Schwalbe, Nina; Simons, Emily; Strebel, Peter M.; Sweet, Steven; Suraratdecha, Chutima; Tam, Yvonne; Vynnycky, Emilia; Walker, Neff; Walker, Damian; Hansen, Peter M.

doi:10.1016/j.vaccine.2012.11.035

Cited by 127 publications

(113 citation statements)

References 61 publications

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…From each of these disease-specific models, [20][21][22] we were given national estimates of the numbers of future deaths and cases averted over the lifetime of cohorts vaccinated in the period 2016-30. For example, all of the future deaths and cases (that is, those occurring after 2016) averted by vaccines administered in 2016 would be considered to be attributable to vaccination year 2016.…”

mentioning

confidence: 99%

The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries

et al. 2018

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries

et al. 2018

Self Cite

View full text Add to dashboard Cite

“…Introduction of a rotavirus vaccine into Gavi-eligible countries will ensure continued progress in diminishing this burden (2); however, prevention and treatment of other important pathogens remain elusive. The Global Enteric Multicenter Study (GEMS) identified Shigella as one of the top two etiologic agents among toddlers and young children with moderate to severe diarrheal disease (MSD) seeking health care in seven developing countries in sub-Saharan Africa and South Asia (3).…”

mentioning

confidence: 99%

Shigella Vaccine Development: Finding the Path of Least Resistance

Chen

Kotloff

2016

Clin Vaccine Immunol

View full text Add to dashboard Cite

-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide "bioconjugate" directed against Shigella flexneri 2a. Ultimately, the goal is to develop a broad-spectrum Shigella vaccine to address this public health concern. A parenteral Shigella vaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.

show abstract

“…11 The population is stratified into those with maternal immunity, pre-infectious (infected but not yet infectious), infectious and immune, with newborns having maternal immunity lasting 6 months from birth. The Supplemental File provides further details, including the model equations.…”

Section: Description Of the Modelmentioning

confidence: 99%

Modeling the impact of rubella vaccination in Vietnam

Vynnycky

Yoshida

Huyen

et al. 2015

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Supported by GAVI Alliance, measles-rubella vaccination was introduced in Vietnam in 2014, involving a mass campaign among 1-14 year olds and routine immunization of children aged 9 months. We explore the impact on the incidence of Congenital Rubella Syndrome (CRS) during 2013-2050 of this strategy and variants involving women aged 15-35 years. We use an age and sex-structured dynamic transmission model, set up using recently-collected seroprevalence data from Central Vietnam, and also consider different levels of transmission and contact patterns. If the serological profile resembles that in Central Vietnam, the planned vaccination strategy could potentially prevent 125,000 CRS cases by 2050 in Vietnam, despite outbreaks predicted in the meantime. Targeting the initial campaign at 15-35 year old women with or without children aged 9 months-14 years led to sustained reductions in incidence, unless levels of ongoing transmission were medium-high before vaccination started. Assumptions about contact greatly influenced predictions if the initial campaign just targeted 15-35 year old women and/or levels of ongoing transmission were medium-high. Given increased interest in rubella vaccination, resulting from GAVI Alliance funding, the findings are relevant for many countries.

show abstract

The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI Alliance

Cited by 127 publications

References 61 publications

The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries

The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries

Shigella Vaccine Development: Finding the Path of Least Resistance

Modeling the impact of rubella vaccination in Vietnam

Contact Info

Product

Resources

About